Association between Atorvastatin therapy and reduction in pacemaker peak threshold in patient with permanent pacemaker

statins are the most effective drugs for treatment of elevated level of cholesterol. In addition, they exhibit other effects unrelated to their lipid lowering effects (pleiotropic actions). In recent years, experimental and clinical evidences demonstrate that statins exert anti-inflammatory properties. The aim of this study is evaluation of association Atorvastatin in reduction of peak threshold in patients with permanent pacemaker. In these Clinical trial 64 eligible patients that candidate for permanent pacemaker enrolled.After in formed Consent patients randomly divided to two equal groups. In first group atorvastatin 20 mg/daily administered orally for six weeks and second group Considered as Control. Peak atrial and ventricular threshold were measured in beginning of study and in sixth week. The data collected and analyzed and p-v‹ 0.05 considered statistically meaning full. from 32 subjects in Atorvastatin group 17 (53.12 %) were male and 15(46.87%) were female. Average mean age in Atorvastatin and Control group was 72.43±17.27 and 68.59 ±10.98 years respectively. No difference showed in atrial and ventricular threshold in two groups at beginning of study.At end of study atrial threshold in atorvastatin and control group were 0.55±0.23 and 0.45±0.19 respectively (p=0.4) and ventricular threshold in atorvastatin and and control group were 0.73±0.23 (p=0.4). There is no association between atorvastatin therapy and reduction in pacemaker peak arterial and ventricular threshold.